Ipamorelin shows minimal effect No appetite stimulation: Unlike ghrelin itself, Ipamorelin does not significantly activate hunger pathways in published studies Published Research on Ipamorelin Study Model Key Finding Raun et al., 1998 (Eur J Endocrinol) Swine/Human Selective GH release without cortisol/prolactin elevation Johansen et al., 1999 Human (Phase I/II) Dose-response relationship with no significant adverse effects Bowers et al., 2004 Review Comparative analysis of GHRP selectivity profiles Head-to-Head Comparison Research Factor CJC-1295 Ipamorelin Receptor Target GHRH-R GHS-R1a (Ghrelin receptor) Signaling Pathway cAMP / PKA PLC / Calcium GH Release Pattern Amplifies natural pulsatile release Induces acute GH pulse Cortisol Impact Minimal Minimal Prolactin Impact Minimal Minimal Research Focus Sustained GH elevation models Selective/clean GH pulse models Typical Research Duration No DAC: 30min half-life / DAC: days ~2 hour half-life Why Researchers Study Them Together The combination of a GHRH analog (CJC-1295) with a GHRP (Ipamorelin) is well-documented in published literature
What makes BPC-157 particularly interesting from a cardiovascular standpoint is its multi-pathway activity
Receive your medication at home
When used at regular doses there are rarely any sides
Your GP or diabetes specialist can help you develop a safe discontinuation plan if appropriate, which may include transitioning to alternative medications, intensifying lifestyle interventions, or implementing more frequent monitoring of blood glucose levels (typically HbA1c at around 3 months post-cessation, or earlier if symptoms develop)
It can help reduce your appetite and prevent weight gain, which may support your weight loss efforts
